• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗后可改变危险因素数量对临床结局的影响:来自e-Ultimaster注册研究的分析

Impact of the number of modifiable risk factors on clinical outcomes after percutaneous coronary intervention: An analysis from the e-Ultimaster registry.

作者信息

Kobo Ofer, Levi Yaniv, Abu-Fanne Rami, Von Birgelen Clemens, Guédès Antoine, Aminian Adel, Laanmets Peep, Dewilde Willem, Witkowski Adam, Monsegu Jacques, Romo Iniguez Andres, Halabi Majdi, Mamas Mamas A, Roguin Ariel

机构信息

Hillel Yaffe Medical Center, Technion-Faculty of Medicine, Hadera, Israel.

Thoraxcentrum Twente, Medisch Spectrum Twente, and Department Health Technology and Services Research, University of Twente, Enschede, The Netherlands.

出版信息

Int J Cardiol Heart Vasc. 2024 Feb 26;51:101370. doi: 10.1016/j.ijcha.2024.101370. eCollection 2024 Apr.

DOI:10.1016/j.ijcha.2024.101370
PMID:38628296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11018637/
Abstract

AIMS

A substantial proportion of the patients undergoing percutaneous coronary intervention (PCI) have none of the of standard modifiable cardiovascular risk factors (SMuRFs): hypertension, diabetes, hypercholesterolaemia and smoking. The aim of this analysis was to compare clinical outcomes after PCI according to the number of SMuRFs.

METHODS

Patients with an indication for a PCI were stratified based upon the number of SMuRFs: 0, 1, 2 or 3-4. The primary outcome was target lesion failure (TLF), a composite of cardiac death, target vessel-related myocardial infarction or clinically driven target lesion revascularization at 1-year. Inverse weighted propensity score (IWPS) adjustment was performed to adjust for differences in baseline characteristics.

RESULTS

The prevalence of SMuRFs was: 0 SMuRF 16.4 %; 1 SMuRF 27.8 %; 2 SMuRFs 34.7 % and 3-4 SMuRFs 21.1 %. Patients without SMuRFs were younger, more likely to be male and had less complex coronary artery disease. The incidence of TLF increased with the number of SMuRFs: 2.65 %, 2.75 %, 3.23 %, and 4.24 %, P < 0.001. The relative risk (RR) for a TLF was 60 % higher (95 % confidence interval 1.32-1.93, p < 0.01) for patients with 3-4 SMuRFs compared to patients without SMuRFs. The trend remained (P < 0.01) after IWPS with TLF rates of 2.88 %, 2.64 %, 2.88 % and 3.65 %. The RR for a TLF was 27 % higher (95 % CI 1.05-1.53, p < 0.01).

CONCLUSION

The incidence of clinical events at 1-year increased with the number of SMuRFs. While patients without SMuRFs have a relatively favourable risk profile, more research is needed to optimize therapeutic management in the majority of patients.

摘要

目的

接受经皮冠状动脉介入治疗(PCI)的患者中,很大一部分没有标准的可改变心血管危险因素(SMuRFs),即高血压、糖尿病、高胆固醇血症和吸烟。本分析的目的是根据SMuRFs的数量比较PCI术后的临床结局。

方法

根据SMuRFs的数量将有PCI指征的患者分层:0个、1个、2个或3 - 4个。主要结局是靶病变失败(TLF),即1年内心脏死亡、靶血管相关心肌梗死或因临床原因导致的靶病变血运重建的复合终点。采用逆加权倾向评分(IWPS)调整来校正基线特征的差异。

结果

SMuRFs的患病率分别为:0个SMuRFs占16.4%;1个SMuRFs占27.8%;2个SMuRFs占34.7%;3 - 4个SMuRFs占21.1%。没有SMuRFs的患者更年轻,男性比例更高,冠状动脉疾病的复杂性更低。TLF的发生率随SMuRFs数量的增加而升高:分别为2.65%、2.75%、3.23%和4.24%,P < 0.001。与没有SMuRFs的患者相比,有3 - 4个SMuRFs的患者发生TLF的相对风险(RR)高60%(95%置信区间1.32 - 1.93,p < 0.01)。IWPS调整后该趋势仍然存在(P < 0.01),TLF发生率分别为2.88%、2.64%、2.88%和

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/ae42c846945d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/58792e18adc4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/a2a033b860f4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/ae42c846945d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/58792e18adc4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/a2a033b860f4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/11018637/ae42c846945d/gr3.jpg

相似文献

1
Impact of the number of modifiable risk factors on clinical outcomes after percutaneous coronary intervention: An analysis from the e-Ultimaster registry.经皮冠状动脉介入治疗后可改变危险因素数量对临床结局的影响:来自e-Ultimaster注册研究的分析
Int J Cardiol Heart Vasc. 2024 Feb 26;51:101370. doi: 10.1016/j.ijcha.2024.101370. eCollection 2024 Apr.
2
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.非标准可调节风险因素的 STEMI 患者的死亡率:SWEDEHEART 注册研究数据的性别细分分析。
Lancet. 2021 Mar 20;397(10279):1085-1094. doi: 10.1016/S0140-6736(21)00272-5. Epub 2021 Mar 9.
3
Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction: Insights from the nationwide Japanese percutaneous coronary intervention registry.无标准可调节风险因素的急性心肌梗死患者行直接经皮冠状动脉介入治疗的特征和结局:来自全国性日本经皮冠状动脉介入治疗注册研究的启示。
Am Heart J. 2023 Apr;258:69-76. doi: 10.1016/j.ahj.2023.01.009. Epub 2023 Jan 13.
4
Impact of peripheral artery disease on prognosis after percutaneous coronary intervention: Outcomes from the multicenter prospective e-ULTIMASTER registry.外周动脉疾病对经皮冠状动脉介入治疗后预后的影响:多中心前瞻性e-ULTIMASTER注册研究结果
Atherosclerosis. 2022 Mar;344:71-77. doi: 10.1016/j.atherosclerosis.2022.01.007. Epub 2022 Jan 25.
5
Prevalence and outcomes of patients with SMuRF-less acute coronary syndrome undergoing percutaneous coronary intervention.SMuRF 缺失型急性冠状动脉综合征患者行经皮冠状动脉介入治疗的患病率和结局。
Open Heart. 2024 Jun 5;11(1):e002733. doi: 10.1136/openhrt-2024-002733.
6
Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry.首次出现 ST 段抬高心肌梗死患者的标准可修正风险因素数量与死亡率:来自中国急性心肌梗死注册登记研究的观察。
BMC Med. 2022 Jul 6;20(1):217. doi: 10.1186/s12916-022-02418-w.
7
In-hospital and 1-year outcomes of patients without modifiable risk factors presenting with acute coronary syndrome undergoing PCI: a Sex-stratified analysis.接受经皮冠状动脉介入治疗(PCI)的无可控危险因素急性冠状动脉综合征患者的院内及1年预后:一项性别分层分析
Front Cardiovasc Med. 2023 Dec 20;10:1235667. doi: 10.3389/fcvm.2023.1235667. eCollection 2023.
8
Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry.多部位动脉疾病对经皮冠状动脉介入治疗后临床结局的影响:来自 e-Ultimaster 登记研究的分析。
Eur Heart J Qual Care Clin Outcomes. 2023 Jun 21;9(4):417-426. doi: 10.1093/ehjqcco/qcac043.
9
Mortality and Cardiovascular Outcomes in Patients Presenting With Non-ST Elevation Myocardial Infarction Despite No Standard Modifiable Risk Factors: Results From the SWEDEHEART Registry.尽管没有标准可改变的风险因素,但出现非 ST 段抬高型心肌梗死的患者的死亡率和心血管结局:来自 SWEDEHEART 登记处的结果。
J Am Heart Assoc. 2022 Aug 2;11(15):e024818. doi: 10.1161/JAHA.121.024818. Epub 2022 Jul 25.
10
Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors - rationale and design of the "Beyond-SMuRFs Study".无标准可调节风险因素的患者中临床、实验室和影像学生物标志物与急性心肌梗死发生的相关性研究 - "Beyond-SMuRFs 研究"的原理和设计。
BMC Cardiovasc Disord. 2023 Mar 23;23(1):149. doi: 10.1186/s12872-023-03180-4.

引用本文的文献

1
Recent highlights from the International Journal of Cardiology Heart & Vasculature: cardiometabolic disease.《国际心脏病学杂志:心脏与血管》近期亮点:心脏代谢疾病。
Int J Cardiol Heart Vasc. 2025 Aug 28;60:101779. doi: 10.1016/j.ijcha.2025.101779. eCollection 2025 Oct.
2
Recent highlights from the : cardio-oncology.心血管肿瘤学的近期要点。 (注:原句中“from the : cardio-oncology”表述有误,推测完整可能是“Recent highlights from the field of cardio-oncology”,按纠正后内容翻译)
Int J Cardiol Heart Vasc. 2025 Aug 27;60:101780. doi: 10.1016/j.ijcha.2025.101780. eCollection 2025 Oct.
3
In-hospital pulse pressure variability: A novel marker of cardiovascular risk among patients with coronary artery disease undergoing percutaneous coronary intervention?

本文引用的文献

1
Ethnic Disparities in ST-Segment Elevation Myocardial Infarction Outcomes and Processes of Care in Patients With and Without Standard Modifiable Cardiovascular Risk Factors: A Nationwide Cohort Study.伴有和不伴有标准可改变心血管危险因素的患者在ST段抬高型心肌梗死结局及医疗过程中的种族差异:一项全国性队列研究
Angiology. 2024 Sep;75(8):742-753. doi: 10.1177/00033197231182555. Epub 2023 Jun 12.
2
Frequency and Outcomes of Patients Presenting with Non-ST Elevation Myocardial Infarction (NSTEMI) without Standard Modifiable Risk Factors: A US Healthcare Experience.无标准可改变危险因素的非ST段抬高型心肌梗死(NSTEMI)患者的发病频率及转归:一项美国医疗保健经验
J Clin Med. 2023 May 3;12(9):3263. doi: 10.3390/jcm12093263.
3
住院期间脉压变异性:经皮冠状动脉介入治疗的冠心病患者心血管风险的新标志物?
Int J Cardiol Heart Vasc. 2024 Jun 15;53:101445. doi: 10.1016/j.ijcha.2024.101445. eCollection 2024 Aug.
4
The hasty generalization fallacy: not all coronary artery disease is the same.轻率概括谬误:并非所有冠状动脉疾病都是相同的。
Int J Cardiol Heart Vasc. 2024 Mar 29;51:101393. doi: 10.1016/j.ijcha.2024.101393. eCollection 2024 Apr.
Mortality in ST-segment elevation myocardial infarction patients without standard modifiable risk factors: A race disaggregated analysis.
无标准可改变风险因素的ST段抬高型心肌梗死患者的死亡率:一项种族分类分析。
Int J Cardiol Heart Vasc. 2022 Oct 10;43:101135. doi: 10.1016/j.ijcha.2022.101135. eCollection 2022 Dec.
4
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients.急性冠状动脉综合征患者无标准可调节风险因素时死亡率更高:来自全球 1285722 例患者的荟萃分析结果。
Int J Cardiol. 2023 Jan 15;371:432-440. doi: 10.1016/j.ijcard.2022.09.062. Epub 2022 Sep 27.
5
Management and outcomes of patients admitted with type 2 myocardial infarction with and without standard modifiable risk factors.伴有和不伴有标准可改变危险因素的2型心肌梗死患者的管理与结局
Int J Cardiol. 2023 Jan 15;371:391-396. doi: 10.1016/j.ijcard.2022.09.037. Epub 2022 Sep 18.
6
Mortality and Cardiovascular Outcomes in Patients Presenting With Non-ST Elevation Myocardial Infarction Despite No Standard Modifiable Risk Factors: Results From the SWEDEHEART Registry.尽管没有标准可改变的风险因素,但出现非 ST 段抬高型心肌梗死的患者的死亡率和心血管结局:来自 SWEDEHEART 登记处的结果。
J Am Heart Assoc. 2022 Aug 2;11(15):e024818. doi: 10.1161/JAHA.121.024818. Epub 2022 Jul 25.
7
Clinical Characteristics and Prognosis of Patients With No Standard Modifiable Risk Factors in Acute Myocardial Infarction.急性心肌梗死患者无标准可调节危险因素的临床特征和预后。
Heart Lung Circ. 2022 Sep;31(9):1228-1233. doi: 10.1016/j.hlc.2022.06.666. Epub 2022 Jul 15.
8
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors.无标准可改变心血管危险因素的ST段抬高型心肌梗死患者的临床结局
JACC Cardiovasc Interv. 2022 Jun 13;15(11):1167-1175. doi: 10.1016/j.jcin.2022.03.036.
9
Trends and Outcomes of ST-Segment-Elevation MI in Hospitalized Patients Without Standard Modifiable Cardiovascular Risk Factors.无标准可调节心血管风险因素的住院 ST 段抬高型心肌梗死患者的趋势和结局。
Curr Probl Cardiol. 2022 Sep;47(9):101271. doi: 10.1016/j.cpcardiol.2022.101271. Epub 2022 May 26.
10
Impact of peripheral artery disease on prognosis after percutaneous coronary intervention: Outcomes from the multicenter prospective e-ULTIMASTER registry.外周动脉疾病对经皮冠状动脉介入治疗后预后的影响:多中心前瞻性e-ULTIMASTER注册研究结果
Atherosclerosis. 2022 Mar;344:71-77. doi: 10.1016/j.atherosclerosis.2022.01.007. Epub 2022 Jan 25.